Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03871816 · ClinicalTrials.gov registry record
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 14,532
- Enrollment target
NCT03871816 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 14,532 participants.
The verdict
NCT03871816 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 14,532 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker eligibility for niraparib interventional studies.
Interventions
- OTHER Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,532 participants |
| Start Date | 2019-04-22 |
| Est. Completion | 2022-11-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03871816
The ClinicalTrials.gov registry entry for NCT03871816 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14,532 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis is the first listed.
NCT03871816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03871816 about?
NCT03871816 is a clinical study titled "A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer". The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker eligibility for niraparib interventional studies.
What is the current status of trial NCT03871816?
This trial is currently completed. The enrollment target is 14,532 participants. The study started on 2019-04-22. Estimated completion is 2022-11-22.
What interventions are being tested in trial NCT03871816?
The interventions under investigation include: Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis (OTHER).
Who is sponsoring clinical trial NCT03871816?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.